StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)

Tue, 18 Aug 2026 06:44:39 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $15.00 price target on Actuate Therapeutics (NASDAQ: ACTU).

The analyst commented: "Actuate Therapeutics reported 2Q26 results on August 14, 2026. The company has received FDA clearance to start the Phase 1/2 study of oral elraglusib, which follows the April 2026 IND filing and is expected to start in 2H26 (Exhibit 1). The study is designed to identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) in adult patients with advanced, refractory cancers, and the company has identified refractory metastatic melanoma, NSCLC, colorectal, and pancreatic cancers as the tumor

Form 4 ACTUATE THERAPEUTICS, For: Aug 14 Filed by: SCHMITT DANIEL M

Fri, 14 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26932393.html

Form 4 ACTUATE THERAPEUTICS, For: Aug 14 Filed by: SCHMITT DANIEL M

Fri, 14 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26932393.html

Form 10-Q ACTUATE THERAPEUTICS, For: Jun 30

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930340.html

Form 10-Q ACTUATE THERAPEUTICS, For: Jun 30

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930340.html

Rodman & Renshaw Starts Actuate Therapeutics (ACTU) at Buy

Thu, 30 Jul 2026 07:53:03 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Actuate Therapeutics (NASDAQ: ACTU) with a Buy rating and a price target of $6.00.

The analyst comments "We are initiating coverage of Actuate Therapeutics with a BUY rating and $6 price target. A $25 million market capitalization does not begin to price three compounding forces working in the company's favor, in our view. The first is randomized Phase 2 survival signal in frontline metastatic pancreatic ductal adenocarcinoma generated by the company's first-in-class GSK-3β inhibitor, Elraglusib. The second is a mechanistically inevitable role as the resistance-breaking partner in the KRAS inhibitor era.

Rodman & Renshaw Starts Actuate Therapeutics (ACTU) at Buy

Thu, 30 Jul 2026 07:53:03 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Actuate Therapeutics (NASDAQ: ACTU) with a Buy rating and a price target of $6.00.

Form 8-K ACTUATE THERAPEUTICS, For: Jul 15

Fri, 17 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260717/26784732.html

Form 8-K ACTUATE THERAPEUTICS, For: Jul 15

Fri, 17 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260717/26784732.html

H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)

Wed, 10 Jun 2026 07:13:13 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $15.00 price target on Actuate Therapeutics (NASDAQ: ACTU).

The analyst commented: "On June 9, Actuate announced elraglusib's inclusion in a multi-arm, multi-stage, randomized, open-label Phase 1/2 study, BEACON2, to evaluate the drug as a therapy for pediatric relapsed or refractory neuroblastoma (NBL). Elraglusib is expected to be combined with dinutuximab beta and chemotherapy. The study, sponsored and operated by the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham, is designed to determine safety, MTD, RP2D, and PK in a cohort of up to 20 patients initially. If

Actuate's elraglusib selected for BEACON2 pediatric neuroblastoma trial

Tue, 09 Jun 2026 07:45:44 -0400

Actuate Therapeutics Inc. (NASDAQ: ACTU) announced that its drug candidate elraglusib will be evaluated in the BEACON2 clinical trial for children with relapsed and refractory neuroblastoma.

The BEACON2 trial is a multi-arm, multi-stage Phase 1/2 platform study conducted by the Cancer Research UK Clinical Trials Unit at the University of Birmingham. Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in up to 20 patients initially to determine safety, maximum tolerated dose, and recommended Phase 2 dose.

The combination may advance to a randomized portion of the trial with approximately 75 patients if the initial phase shows positive results. The

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

Tue, 09 Jun 2026 07:45:00 -0400

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham

- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma

- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers

- Elraglusib has received FDA Rare Pediatric Disease designation for neuroblastoma